Bioactive IGF-I Concentrations in Children on GH Therapy - Takeaways - MDSpire

Bioactive IGF-I Concentrations in Children on GH Therapy

  • By

  • Lea Vilmann

  • Jakob Albrethsen

  • Jørgen Holm Petersen

  • Stine Agergaard Holmboe

  • Peter Christiansen

  • Katharina Maria Main

  • Line Cleemann

  • Kristian Horsman Hansen

  • Jan Frystyk

  • Casper P Hagen

  • Anders Juul

  • October 14, 2025

  • 0 min

Share

  • 1

    Monitoring bioactive IGF-I levels during GH therapy in children is crucial for optimizing treatment and minimizing long-term risks.

  • 2

    In a study, 13% of GH-treated patients had bioactive IGF-I above +2SD, while 25% had total IGF-I above +2SD.

  • 3

    Bioactive IGF-I levels increased with age in healthy children and correlated positively with total IGF-I and IGF-I/IGFBP-3.

  • 4

    Total IGF-I may not be an appropriate efficacy marker for non-GHD conditions, serving better as a safety parameter.

  • 5

    The study established pediatric, sex-specific reference ranges for bioactive IGF-I to aid in monitoring GH therapy.

Original Source(s)

Bioactive IGF-I Concentrations in Children on GH Therapy

  • by Lea Vilmann, Jakob Albrethsen, Jørgen Holm Petersen, Stine Agergaard Holmboe, Peter Christiansen, Katharina Maria Main, Line Cleemann, Kristian Horsman Hansen, Jan Frystyk, Casper P Hagen, Anders Juul

  • October 14, 2025

Related Content

Physicians Exiting Practice Earlier

Researchers identify burnout-associated workplace pressures and caregiving responsibilities as major contributors to physician attrition.

A serum exosomal four-miRNA signature for the diagnosis of central precocious puberty: a discovery and validation study

Surgical outcomes of Bethesda System for Reporting Thyroid Cytopathology diagnostic category class I, II, and III thyroid nodules